Search Results - "Kowalyszyn, Ruben D"

Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-Blinded, Noninferiority Study by Kowalyszyn, Ruben D, Fein, Luis E, Richardet, Martin E, Varela, Mirta S, Ortiz, Eduardo, Micheri, Cristian, Zarba, Juan J, Kahl, Susana, Klimovsky, Ezequiel, Federico, Andrea A, Cassini, Jorge H, Cortese, Gustavo, Lago, Nestor

“…This study evaluated the efficacy, safety, and immunogenicity of biosimilar pegfilgrastim (PegFilBS) and originator pegfilgrastim (PegFilOR) in patients with…”
Get full text

Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer by Rugo, Hope S, Umanzor, Gerardo A, Barrios, Francisco J, Vasallo, Rosa H, Chivalan, Marco A, Bejarano, Suyapa, Ramírez, Julio R, Fein, Luis, Kowalyszyn, Ruben D, Kramer, E Douglas, Wang, Hui, Kwan, Min-Fun R, Cutler, David L

“…Intravenous paclitaxel (IVpac) is complicated by neuropathy and requires premedication to prevent hypersensitivity-type reactions. Paclitaxel is poorly…”
Get full text

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial by Garon, Edward B, Dr, Ciuleanu, Tudor-Eliade, Prof, Arrieta, Oscar, MD, Prabhash, Kumar, Prof, Syrigos, Konstantinos N, Prof, Goksel, Tuncay, Prof, Park, Keunchil, Prof, Gorbunova, Vera, MD, Kowalyszyn, Ruben Dario, MD, Pikiel, Joanna, MD, Czyzewicz, Grzegorz, MD, Orlov, Sergey V, Prof, Lewanski, Conrad R, MD, Thomas, Michael, Prof, Bidoli, Paolo, MD, Dakhil, Shaker, MD, Gans, Steven, MD, Kim, Joo-Hang, Prof, Grigorescu, Alexandru, Prof, Karaseva, Nina, MD, Reck, Martin, MD, Cappuzzo, Federico, MD, Alexandris, Ekaterine, MS, Sashegyi, Andreas, PhD, Yurasov, Sergey, MD, Pérol, Maurice, MD

“…Summary Background Ramucirumab is a human IgG1 monoclonal antibody that targets the extracellular domain of VEGFR-2. We aimed to assess efficacy and safety of…”
Get full text